

Keywords: breast cancer; smoking; endocrine treatment; aromatase inhibitor; tamoxifen; prognosis

Impacts of smoking on endocrine treatment response in a prospective breast cancer cohort

Mia Persson¹, Maria Simonsson¹, Andrea Markkula¹, Carsten Rose², Christian Ingvar³ and Helena Jernström^{*,1}

¹Department of Clinical Sciences, Lund, Division of Oncology and Pathology, Lund University, Barngatan 2B, 22185 Lund, Sweden;

²CREATE Health and Department of Immunotechnology, Lund University, Medicon Village (Building 406), 223 81 Lund, Sweden and

³Department of Clinical Sciences, Lund, Division of Surgery, Lund University and Skåne University Hospital, 22185 Lund, Sweden

Background: The association between smoking and breast cancer prognosis remains unclear. The purpose of this study was to investigate whether preoperative smoking was associated with prognosis in different treatment groups.

Methods: This population-based cohort consisted of 1065 breast cancer patients without preoperative treatment included between 2002 and 2012 in Lund, Sweden. Smoking status was examined in relation to patient and tumour characteristics, and prognosis in different treatment groups.

Results: At the preoperative visit, 21.0% smoked. Median follow-up time was 5.1 years. Overall, in the 1016 patients included in the survival analyses, there was no significant association between smoking and risk of breast cancer events (adjusted hazard ratio (adjHR): 1.45; 95% confidence interval (CI): 0.95–2.20). For the 309 aromatase inhibitor (AI)-treated patients ≥ 50 years with oestrogen receptor-positive (ER+) tumours, smoking was associated with risk of breast cancer events (adjHR: 2.97; 95% CI: 1.44–6.13), distant metastasis (adjHR: 4.19; 95% CI: 1.81–9.72), and death (adjHR: 3.52; 95% CI: 1.59–7.81). Smoking was not associated with breast cancer events or distant metastasis in other treatment groups.

Conclusions: Preoperative smoking was only associated with an increased risk for breast cancer events and distant metastasis in AI-treated patients. If confirmed, smoking status should be taken into consideration when selecting an endocrine therapy.

Breast cancer is the most common cancer among women worldwide (Ferlay *et al*, 2014). Identification of modifiable lifestyle factors that may improve prognosis is of interest to women diagnosed with breast cancer. Several studies have investigated the association between smoking and prognosis in breast cancer patients. Smoking is associated with an overall increased mortality. However, the association between smoking and breast cancer-specific mortality or disease-free survival remains unclear. Some studies found no significant association (Holmes *et al*, 2007; Berube *et al*, 2014; Seibold *et al*, 2014), whereas others found an increased risk for recurrence or breast cancer-specific mortality (Manjer *et al*, 2000; Braithwaite *et al*, 2012; Bishop *et al*, 2014;

Pierce *et al*, 2014; Nechuta *et al*, 2016; Passarelli *et al*, 2016). Moreover, this association was sometimes only reported in current smokers or in patients with more extensive smoking.

In 2013, ~11% of the female population in Sweden smoked cigarettes daily, and an additional 9% smoked occasionally (Public Health Agency of Sweden (Folkhälsomyndigheten), 2013). Cigarette smoke contains over 7000 chemicals, 69 of which are established carcinogens (United States Department of Health and Human Services, 2010). Smoking has anti-oestrogenic effects and decreases endogenous oestrogen (Baron, 1984). Constituents of cigarettes such as nicotine and other tobacco alkaloids inhibited oestrogen synthesis via the aromatase enzyme when tested *in vitro*

*Correspondence: Dr H Jernström; E-mail: Helena.Jernstrom@med.lu.se

Received 16 November 2015; revised 11 May 2016; accepted 16 May 2016; published online 9 June 2016

© 2016 Cancer Research UK. All rights reserved 0007–0920/16

(Barbieri *et al*, 1986; Kadohama *et al*, 1993). However, current smoking is also associated with increased levels of urinary prostaglandin E₂ metabolites (Kim *et al*, 2013). Prostaglandin E₂ is synthesised from arachidonic acid via the action of cyclooxygenase 2 and is a key mediator of inflammation (Park *et al*, 2006) that increases aromatase activation (Subbaramaiah *et al*, 2012). The net effect of smoking on aromatase activity in different women may vary.

Little is known about how smoking influences response to different types of breast cancer treatments. Smoking has been reported to impact the response to both radiation and chemotherapy, primarily in other cancers (An *et al*, 2012; Hoff *et al*, 2012; Trevino *et al*, 2012; Bishop *et al*, 2014; Guha *et al*, 2014). Endocrine therapy represents one of the most effective treatments for women with oestrogen receptor-positive (ER+) breast cancers. Two classes of agents are the selective ER modulators, for example, tamoxifen (TAM) and aromatase inhibitors (AIs) (Jordan, 2006; Dowsett *et al*, 2010). To our knowledge, no study has investigated a potential association between smoking and response to different types of endocrine therapy. We hypothesise that smoking may be associated with the response to endocrine treatment as smoking affects endogenous oestrogen levels via the aromatase enzyme, and that any association may differ between TAM and AIs because of their different mechanisms of action.

The aim of this study was to examine if the prognosis differed between smokers and non-smokers among patients who had received different types of breast cancer treatment, with a special focus on the endocrine treatment response.

MATERIALS AND METHODS

Patients of all ages diagnosed with a first breast cancer at the Skåne University Hospital in Lund, Sweden were included between October 2002 and June 2012 in an ongoing prospective cohort study of lifestyle factors and their association with prognosis and treatment response ($n = 1116$). There were a total of 2170 female patients operated for breast cancer during the time period this cohort was compiled. Only patients with primary breast cancer and no other cancer during the past 10 years were included in the cohort. The total number also included patients with a secondary breast cancer as well as patients who had been diagnosed with other cancers within the past 10 years. The median age of all patients was 61 years. Oestrogen receptor status was available for 1928 patients, of whom 85.4% had ER+ tumours. Progesterone receptor (PgR) status was available for 1914 patients, of whom 70.1% had PgR+ tumours. For the present study, 51 patients who had received preoperative treatment were excluded, leaving 1065 patients (see Figure 1). The study was approved by the Lund University Ethics Committee (LU Dnr75-02, Dnr37-08, Dnr658-09, Dnr58-12, Dnr379-12, Dnr 277-15, Dnr458-15), and written informed consents were obtained from all participants.

Participating patients completed a three-page questionnaire at the preoperative visit. Follow-up questionnaires were completed 3–6 months, and 1, 2, 3, 5, 7, 9 and 11 years postoperatively. The questionnaire included questions regarding medication intake during the last week, reproductive history, and smoking and alcohol consumption. The follow-up questionnaires also provided information on adjuvant treatment. Anthropometric measures including height, weight, waist and hip circumferences, and breast volume were measured with plastic cups by trained research nurses, as described previously (Ringberg *et al*, 2006; Markkula *et al*, 2012a).

The patients were asked to define themselves as non-smokers, smokers, or occasional smokers. The approximate number of cigarettes consumed during the last week was obtained as an interval (0, 1–5, 6–10, 11–15, 16–20, 20+). Patients who considered themselves as either smokers or occasional smokers or who had reported to have smoked >0 cigarettes were defined as 'smokers'.

Tumours were analysed at the Department of Pathology at the Skåne University Hospital, Lund, Sweden. Information on tumour size, axillary lymph node involvement, histological grade, and ER and PgR status (positive if >10% nuclei were stained according to standard clinical practice in Sweden) was obtained from each patient's pathology report, as described previously (Bågeman *et al*, 2008; Jernström *et al*, 2009; Simonsson *et al*, 2014). The human epidermal growth factor receptor 2 (HER2) status was routinely analysed as of November 2005 in patients younger than 70 years of age with invasive tumours, as described previously (Markkula *et al*, 2014), and is thus missing for a substantial part of the tumours. Analyses of Ki-67 index were routinely performed as of March 2009 and are therefore not included.

Information regarding breast cancer events – defined as either local or regional recurrence, new breast cancer, or distant metastases – and date of death owing to any cause was collected from the patients' charts, pathology reports, regional tumour registry, and population registry. Information regarding treatment was obtained from the patients' charts as well as from the questionnaires. Only treatment before any breast cancer event was considered. The study was observational, and treatment was provided according to the standard of care at the Skåne University Hospital.

Statistical analysis. All statistical analyses were performed using IBM Statistical Package for Social Sciences (SPSS) version 19.0 (IBM Corp., Armonk, NY, USA). Patient and tumour characteristics were analysed in relation to smoking status at the preoperative visit. Total breast volume for both breasts was calculated for those with no previous breast surgery (Ringberg *et al*, 2006; Markkula *et al*, 2012a). Tumour characteristics included invasive tumour size (≤ 20 mm, 21–50 mm, ≥ 51 mm, muscle or skin involvement or ≥ 21 mm, or muscle or skin involvement (yes/no)), pathological axillary lymph node involvement (0, 1–3, 4+, or axillary lymph node involvement (yes/no)), histological grade (I–III or grade III (yes/no)), hormone receptor status (ER+, PgR+), and HER2 status (amplified/not amplified). For analysis of categorical variables in relation to smoking status, Pearson's χ^2 test was used. If the expected number of patients in one or more categories was <5, Fisher's exact test was used. Continuous variables were analysed using the Mann–Whitney U -test for the univariable analyses. Variables that were not normally distributed were categorised for the multivariable analyses.

Response to given treatments, measured as risk of breast cancer events, was analysed in relation to preoperative smoking status. For these analyses, patients with carcinoma *in situ* ($n = 39$), metastatic spread within 0.3 years from inclusion ($n = 8$), or missing preoperative smoking status ($n = 2$) were excluded. The follow-up time was calculated as the time from inclusion until a first breast cancer event, death from a non-breast cancer-related cause, or last follow-up for patients who were alive and event-free before 1 July 2014. Patients were censored at the time of a non-breast cancer-related death or last follow-up. Similarly, follow-up time until distant metastasis was calculated as the time from inclusion until a first distant metastasis, death from a non-breast cancer-related cause, or last follow-up for patients who were alive and distant metastasis-free before 1 July 2014. Time to death owing to any cause was calculated as the time from inclusion until death or last follow-up before 1 July 2014. For the 1016 patients included in these analyses, there were 122 breast cancer events, out of which 76 were distant metastases. A total of 97 patients had died during follow-up, and 39 of these had no reported breast cancer event.

To evaluate if preoperative smoking status was representative, changes in smoking status during the first postoperative year were assessed using the reported smoking status at the preoperative visit and follow-up visits after 3–6 months and 1 year. Missing data were handled according to the last observation carried forward method. In the case of missing data, the reported smoking status




Figure 1. Flowchart of patients in different analyses in relation to their preoperative smoking status. AIs = aromatase inhibitors; ER = oestrogen receptor; TAM = tamoxifen.

from the previous visit was carried forward if the total follow-up time was longer than 0.5 years for the visit after 3–6 months ($n = 61$) and 1.0 year for the visit after 1 year ($n = 34$). Therefore, if patients had died from non-breast cancer-related causes before 0.5 years postoperatively ($n = 1$) or 1 year postoperatively ($n = 1$), they were not included in the analyses of these visits. Also, patients who were alive and event-free but had a follow-up shorter than 0.5 years or 1 year because they had not been to the visit at 3–6 months ($n = 12$) or 1 year postoperatively ($n = 27$) were not included in the analysis of smoking status at the respective visit. If a breast cancer event occurred before a visit, no last observation carried forward or data collected at this visit were included in the analysis for the visit 3–6 months postoperatively ($n = 2$) and for the visit 1 year postoperatively ($n = 11$). One patient had an event on the day of her visit. The data from this visit was included.

To calculate risk of breast cancer events, distant metastases, or death, Kaplan–Meier estimates were used. Cox’s regressions were used to obtain adjusted hazard ratios (adjHRs) with 95% confidence intervals (CIs). Adjustments were made for invasive tumour size ≥ 21 mm or muscle or skin involvement (yes/no),

axillary lymph node involvement (yes/no), histological grade III (yes/no), positive ER status (yes/no), age (continuous), and body mass index (BMI) ≥ 25 kg m⁻² (yes/no). Further adjustments for treatment factors included ever treatment with radiation therapy (yes/no), chemotherapy (yes/no), TAM (yes/no), and AIs (yes/no).

The questionnaire included questions regarding menopausal status. Owing to risk of misclassification of menopausal status for hormonal therapy users and patients with previous gynaecological surgeries, age ≥ 50 years was used as a proxy variable for postmenopausal status.

A P -value < 0.05 was considered statistically significant, and all P -values were two-sided. Nominal P -values are presented without adjustment for multiple testing.

RESULTS

Patient and tumour characteristics. Out of the 1065 patients included in the study, 223 (21%) reported to be smokers at the time

of the preoperative visit (Table 1). The smokers were in general younger, had a lower body weight, BMI, and preoperative total breast volume. Moreover, the smokers had fewer children, were significantly younger at their first full-term pregnancy, and were more likely to have used oral contraceptives. Tumour characteristics were similar between smokers and non-smokers except for hormone receptor status. Smokers had more often hormone receptor-negative tumours compared with non-smokers (Table 2).

Reported smoking status over time. Risk of breast cancer events in relation to smoking status was analysed in the 1016 patients with invasive tumours and no distant metastases were detected on postoperative metastases screen within 0.3 years of surgery. Of these, 206 were considered smokers and 810 were not considered smokers at the time of the preoperative visit (Figure 1). Figure 2 shows how the smoking habits of these patients changed during the first postoperative year. Less than 1% of the 810 preoperative non-smokers reported smoking at either the 3–6 months or 1-year postoperative visit, whereas about 10% of the patients who smoked preoperatively reported not to smoke during the follow-up visits. Thus, the majority of the patients did not switch smoking status.

Smoking and the risk of breast cancer events and death in different treatment groups. Patients were followed for up to 11 years, and the median follow-up time was 5.1 years (interquartile range (IQR): 3.0–7.2) for the 855 patients who were still alive and at risk of breast cancer events. Overall, there was no significant association between smoking at the preoperative visit and risk of breast cancer events (log rank, $P=0.14$; adjHR: 1.45; 95% CI: 0.95–2.20) adjusted for patient and tumour characteristics (Figure 3A). In all patients, smoking was associated with a two-fold increased risk for death owing to any cause (log rank, $P=0.037$; adjHR: 2.03; 95% CI: 1.29–3.21). No association was observed between smoking and risk of breast cancer events among the 257 chemotherapy-treated patients (log rank, $P=0.69$) (Figure 3B). Among the 639 radiotherapy-treated patients, there

was a tendency towards an increased risk of a breast cancer event among smokers (log rank, $P=0.08$; adjHR: 1.71; 95% CI: 1.02–2.88) (Figure 3C).

Survival analysis in relation to endocrine treatment was restricted to the 891 patients with ER+ tumours. Among the patients younger than 50 years ($n=168$), there was no significant association between smoking and prognosis neither among the 120 patients who had ever received TAM nor among the 35 patients who had ever received AIs (all log rank P s ≥ 0.21).

For the 309 AI-treated patients ≥ 50 years, smoking was significantly associated with an increased risk of breast cancer events (log rank, $P=0.005$; adjHR: 2.97; 95% CI: 1.44–6.13) (Figure 4A), distant metastasis (log rank, $P=0.002$; adjHR: 4.19; 95% CI: 1.81–9.72) (Figure 4B), and death (log rank, $P=0.003$; adjHR: 3.52; 95% CI: 1.59–7.81) (Figure 4C). The absolute risk for breast cancer events was 17.5/1000 person-years among non-smokers and 48.2/1000 person-years for smokers. For the 408 TAM-treated patients ≥ 50 years, smoking was not significantly associated with risk for breast cancer events (log rank, $P=0.39$) (Figure 4D). Among TAM-treated patients never treated with AIs, there was no association between preoperative smoking status and risk for breast cancer events (log rank, $P=0.51$).

Further adjustments for other types of treatment modalities than the one selected did not materially change the result, except for the AI-treated patients where the adjHRs increased after further adjustments for TAM, chemotherapy, and radiotherapy.

As smoking appeared to have the strongest association in the AI-treated patients, stratification according to AI treatment was performed for the patients treated with radiotherapy, where a weak association between smoking and breast cancer events was found. Here, there was a four-fold risk for events in the 233 radiotherapy-treated patients who had received AIs (log rank, $P<0.001$; adjHR: 4.13; 95% CI: 1.66–10.26). No association between smoking and events was observed in the 406 radiotherapy-treated patients who had not received AIs (log rank, $P=0.94$).

Table 1. Patient characteristics in relation to smoking status at the preoperative visit

	All		Smoker at the preoperative visit ^a		
	Median (IQR) or %	Missing	Median (IQR) or %		P-value
	n = 1065		Yes n = 223 (21.0%)	No n = 840 (79.0%)	
Age at diagnosis (years)	61.3 (52.3–68.1)	0	59.0 (51.3–65.4)	61.9 (52.7–69.0)	< 0.001
Year of birth	1946 (1940–1955)	0	1948 (1943–1956)	1945 (1940–1954)	0.001
Weight (kg)	69.0 (62.0–78.0)	27	66.6 (60.0–76.0)	70.0 (62.0–78.5)	< 0.001
Height (m)	1.65 (1.62–1.70)	27	1.65 (1.62–1.69)	1.65 (1.62–1.70)	0.76
BMI (kg m ⁻²)	25.1 (22.5–28.3)	29	24.4 (21.7–27.2)	25.2 (22.7–28.7)	< 0.001
Waist-to-hip ratio	0.86 (0.81–0.90)	39	0.87 (0.82–0.90)	0.85 (0.81–0.90)	0.09
Total breast volume (ml) ^b	1000 (650–1500)	167	800 (600–1300)	1000 (700–1600)	< 0.001
Age at menarche (years)	13 (12–14)	6	13 (12–14)	13 (12–14)	0.55
Parous	87.9%	1	85.7%	88.6%	0.24
Parity	2 (1–3)	1	2 (1–2)	2 (1–3)	0.06
Age at first full-term pregnancy (years) ^c	25 (22–28)	136	23 (20–26)	25 (22–28)	< 0.001
Alcohol abstainer	10.5%	7	7.2%	11.4%	0.07
Ever treated for menopausal symptoms	44.4%	3	39.0%	46.0%	0.06
Ever use of oral contraceptives	70.7%	1	78.0%	68.8%	0.007

Abbreviations: BMI = body mass index; IQR = interquartile range.
^aSmoking status missing for two patients.
^bIn patients without previous breast surgery.
^cIn parous patients. The bold numbers indicate statistical significance.

Table 2. Tumor characteristics in relation to smoking status at the preoperative visit

	All		Smoker at the preoperative visit ^a		P-value
	Number and %		Number and %		
	n = 1065	Yes n = 223 (21%)	No n = 840 (79%)		
Invasive tumour size					<i>P</i> _{trend} = 0.19
<i>In situ</i>	39 (3.7%)	13 (5.8%)	26 (3.1%)		<i>P</i> = 0.42
1–20 mm	740 (69.5%)	155 (69.5%)	584 (69.5%)		
21–50 mm	269 (25.3%)	51 (22.9%)	217 (25.8%)		
51 or larger	15 (1.4%)	4 (1.8%)	11 (1.3%)		
Muscle or skin involvement	2 (0.2%)	0 (0.0%)	2 (0.2%)		
≥21 or muscle or skin involvement	286 (26.9%)	55 (24.7%)	230 (27.4%)		
Missing	0	0	0		
No. of involved axillary lymph nodes					<i>P</i> _{trend} = 0.55
0	665 (62.6%)	146 (65.5%)	519 (61.9%)		<i>P</i> = 0.33
1–3	307 (28.9%)	57 (25.6%)	249 (29.7%)		
4+	91 (8.6%)	20 (9.0%)	70 (8.4%)		
Axillary node involvement (yes)	398 (37.4%)	77 (34.5%)	319 (38.1%)		
Missing	2	0	2		
Histological grade					<i>P</i> _{trend} = 0.45
I	252 (23.8%)	66 (29.9%)	186 (22.2%)		<i>P</i> = 0.29
II	519 (49.0%)	89 (40.3%)	430 (51.4%)		
III	288 (27.2%)	66 (29.9%)	220 (26.3%)		
Histologic grade III (Yes)	288 (27.2%)	66 (29.9%)	220 (26.3%)		
Missing	6	2	4		
Hormone receptor status					
ER+	899 (87.1%)	176 (82.2%)	722 (88.5%)		<i>P</i> = 0.02
PgR+	728 (70.7%)	135 (63.4%)	592 (72.7%)		<i>P</i> = 0.008
ER+PgR+	722 (70.2%)	132 (62.0%)	589 (72.4%)		<i>P</i> = 0.003
ER+PgR–	176 (17.1%)	43 (20.2%)	133 (16.3%)		<i>P</i> = 0.18
ER–PgR–	125 (12.1%)	35 (16.4%)	89 (10.9%)		<i>P</i> = 0.03
ER–PgR+	6 (0.6%)	3 (1.4%)	3 (0.4%)		<i>P</i> = 0.11 ^b
Missing	36	10	26		
HER2 gene amplification ^c	86 (12.5%)	13 (9.6%)	72 (13.1%)		<i>P</i> = 0.26
Missing	377	87	290		

Abbreviations: ER = oestrogen receptor; HER2 = human epidermal growth factor 2; PgR = progesterone receptor tumours.

^aSmoking status missing for two patients.

^bFisher’s exact test.

^cHER2 was routinely analysed first as of November 2005, and in patients younger than 70 years of age with invasive tumours. The bold numbers indicate statistical significance.




Figure 2. Flowchart of smoking status among alive and event-free patients using ‘last observation carried forward’. Out of the 206 preoperative smokers, 21 patients (10.2%) reported no further smoking during the first postoperative year. Out of the 810 preoperative non-smokers, seven patients (<1%) reported smoking during the first postoperative year.

Similarly, after exclusion of AI-treated patients, there was no association between smoking and breast cancer events (log rank, *P* = 0.98) or distant metastasis (log rank, *P* = 0.51) in the

remaining patients irrespective of age and ER status. However, there was a borderline significant increased risk for death due to any cause among patients who had not received AI treatment, but this was only found in the multivariable model (log rank, *P* = 0.43; adjHR: 1.82; 95% CI: 1.01–3.26).

DISCUSSION

The main finding of the present study was the increased risk of breast cancer events, distant metastasis, and death among AI-treated patients ≥50 years who smoked at the preoperative visit compared with non-smokers. To our knowledge, this association has not been previously reported. Smoking was not associated with breast cancer events or distant metastases in other treatment groups.

In line with several other large studies including between 792 and 20 691 patients, current smoking was associated with a two-fold increased risk for death due to any cause (Manjer *et al*, 2000; Holmes *et al*, 2007; Braithwaite *et al*, 2012; Berube *et al*, 2014; Pierce *et al*, 2014; Seibold *et al*, 2014; Nechuta *et al*, 2016; Passarelli *et al*, 2016), with effect sizes ranging from 1.34 to 2.63. These studies also had access to data on former smoking history and five of them showed an increased risk for death also with former




Figure 3. Kaplan–Meier estimates showing the association between preoperative smoking status and risk for breast cancer events. As this is an ongoing cohort, there are fewer patients with longer follow-up times. (A) There was no association among all patients. (B) There was no association among patients ever treated with chemotherapy. (C) Smoking was associated with a tendency towards an increased risk for breast cancer events among patients ever treated with radiotherapy. adjHR = adjusted hazard ratios; CI = confidence interval.

smoking (Braithwaite *et al*, 2012; Berube *et al*, 2014; Pierce *et al*, 2014; Nechuta *et al*, 2016; Passarelli *et al*, 2016). However, in two of these studies, this association was only found in former smokers with 20+ pack-years (Pierce *et al*, 2014; Nechuta *et al*, 2016). These two latter studies were partly based on the same study population and smoking was assessed on average 2 years after diagnosis, thus excluding early events. Only one other study examined current smoking in relation to all-cause mortality in different treatment groups. This study stratified according to TAM treatment, radiotherapy, and chemotherapy and reported no increased risk, but showed no data on AI treatment (Holmes *et al*, 2007). Their finding of no increased risk in patients treated with TAM, radiotherapy, or chemotherapy is in line with the results of the present study. Eight of these studies investigated breast cancer-specific survival (Manjer *et al*, 2000; Holmes *et al*, 2007; Braithwaite *et al*, 2012; Berube *et al*, 2014; Pierce *et al*, 2014; Seibold *et al*, 2014; Nechuta *et al*, 2016; Passarelli *et al*, 2016), of which five reported a statistically significant increased risk for current smokers ranging between 1.25 and 2.14 (Manjer *et al*, 2000;

Braithwaite *et al*, 2012; Pierce *et al*, 2014; Nechuta *et al*, 2016; Passarelli *et al*, 2016). Risk for recurrence with current smoking ranged from 1.05 to 1.41 in four studies, but was significant only in the one study with the highest estimate (Pierce *et al*, 2014) and not in the three other studies (Holmes *et al*, 2007; Seibold *et al*, 2014; Nechuta *et al*, 2016). In the study by Nechuta *et al* (2016), former smokers with 20+ pack-years had a statistically increased risk for recurrence. Their study examined late recurrences 5+ years postdiagnosis and only included patients with ER+ tumours (Nechuta *et al*, 2016). In the present study, former smokers were grouped with never smokers and this may have attenuated the results. None of the referenced eight former studies took AI treatment into account and the vast majority of patients were included before routinely available AI treatment.

There could be several mechanisms behind the results in the present study of a worse short-term prognosis in AI-treated patients. In line with other studies (Albanes *et al*, 1987; Barrett-Connor and Khaw, 1989; Molarius *et al*, 1997; Holmes *et al*, 2007; Abramowitz *et al*, 2010; Braithwaite *et al*, 2012; Kwok *et al*, 2012;




Figure 4. Kaplan–Meier estimates showing the association between preoperative smoking status and risk of breast cancer events, distant metastases, and death due to any cause among patients ≥ 50 years with ER + tumours. As this is an ongoing cohort, there are fewer patients with longer follow-up times. **(A)** Smoking was associated with a three-fold increased risk for breast cancer events among AI-treated patients. **(B)** Smoking was associated with a four-fold increased risk for distant metastases among AI-treated patients. **(C)** Smoking was associated with a three-fold increased risk of death due to any cause among AI-treated patients. **(D)** There was no association between smoking and risk for breast cancer events among TAM-treated patients. AdjHR = adjusted hazard ratios; als = aromatase inhibitors; CI = confidence interval; ER = oestrogen receptor; TAM = tamoxifen.

Berube *et al*, 2014; Huzell *et al*, 2015), several patient characteristics that may influence prognosis differed between smokers and non-smokers in the present study. We have previously reported higher frequency of smoking with increasing pre- and post-operative alcohol intake in the present cohort (Simonsson *et al*, 2014). However, alcohol intake was not associated with increased risk for events in any treatment group in this cohort and cannot explain the association between smoking and risk for events in AI-treated patients. Smokers had lower BMIs but a tendency towards larger waist-to-hip ratios and smaller breast volumes than non-smokers. These anthropometric factors have been associated with a more androgenic profile (Björntorp, 1997; Baglietto *et al*, 2009) that may influence AI response (Morris *et al*, 2001). Smoking may also be associated with other patient characteristics that were not assessed in this study such as patterns of physical activity that may influence prognosis (Nechuta *et al*, 2016).

Smoking was also associated with hormone receptor-negative tumours in the present cohort, whereas results from other studies are conflicting. A cohort of over 2000 breast cancer cases found no association between smoking and hormone receptor status (Braithwaite *et al*, 2012). A large cohort of 148 000 women reported an increased risk for ER + cancer but no association with incident triple-negative cancer with over 40 pack-years of smoking (Kabat *et al*, 2011), which is in line with another large cohort of 117 000 women who reported smoking to be weakly associated with development of ER + tumours (London *et al*, 1989). Conversely, smoking was significantly associated with development of hormone receptor-negative breast cancer in a South Swedish cohort of 10 000 women (Manjer *et al*, 2001). In Sweden, tumours are considered ER + when $>10\%$ of the nuclei are stained, whereas other countries have a cutoff of $>1\%$. Exact ER levels were unavailable in the present study, but according to a review, it

remains unclear to what extent hormone receptor levels impact on treatment response (Rastelli and Crispino, 2008).

Nicotine and tobacco alkaloids have been shown to inhibit oestrogen synthesis via the aromatase enzyme *in vitro* (Barbieri *et al*, 1986; Kadohama *et al*, 1993). Tumours that develop in smokers may already be resistant to AIs. In the present study, there were no data regarding smoking history. Former smokers were analysed as non-smokers. If smoking renders the tumour AI-resistant, this would have led to a bias towards the null. Data on former smoking would have enabled analyses of whether the tumours were already resistant to AIs irrespective of smoking status during AI treatment. If the tumour were AI-resistant, smokers could be offered TAM, as smoking was not associated with prognosis in TAM-treated patients. Cigarette smoke may also interact with therapy through upregulation of cytochrome P450 enzymes such as CYP1A2 that is involved in both metabolism of oestrogens and AIs (Grimm and Dyroff, 1997; Schrenk *et al*, 1998; Tsuchiya *et al*, 2005; Kamdem *et al*, 2011). Moreover, CYP1A2 genotypes predicted short-term prognosis in AI-treated patients from a subset of this cohort (Simonsson *et al*, 2016). If cigarette smoke interacts with AIs, smokers assigned to AIs should be encouraged to quit. As only 10% of the preoperative smokers in the present study quit during the first year of follow-up, evaluation of smoking cessation was not possible.

Smokers tended to have a somewhat shorter duration of endocrine treatment (data not shown), and this may in part explain the increased risk of events among AI-treated smokers. Previous work from the same cohort reported that preoperative smokers are more likely to be non-adherent to endocrine therapy (Markkula *et al*, 2012b). However, this does not explain why there was no association between smoking and risk for events in TAM-treated patients.

This study has some limitations. No data on former smoking habits, socioeconomic status, or exact ER levels were collected. Also, the mechanisms behind the association between smoking and worse prognosis in AI-treated patients remain to be elucidated. A strength of the present study was that it is population-based, as patients were not referred to other hospitals for surgery. The majority of the female patients with primary breast cancer that fit the inclusion criteria participated in the study, and the main reason for non-participation was lack of available research nurses, where non-inclusion was unrelated to characteristics of the patients or their type of tumours. Approximately 5% of patients had an unclear diagnosis at the time of surgery and were therefore not included (Lundin *et al*, 2011). The included patients were comparable to all operated female patients with respect to age but had slightly higher frequency of ER+ and PgR+ tumours. No data were available on socioeconomic status or other tumour characteristics.

Another strength was that information on smoking was collected from questionnaires both pre- and postoperatively and not from patients' charts. As it was a prospective study, the risk for bias in the smoking variable due to survival or recall bias was minimised.

In conclusion, preoperative smoking was only associated with an increased risk for breast cancer events and distant metastasis among AI-treated patients. If confirmed, smoking status should be taken into consideration when selecting endocrine therapy.

ACKNOWLEDGEMENTS

We thank research nurses Anette Ahlin Gullers, Anita Schmidt Casslén Monika Meszaros, Maj-Britt Hedenblad, Karin Henriksson, Anette Möller, Helén Thell, Jessica Åkesson, and Linda Ågren. We also thank Erika Bågeman, Maria Henningson,

and Maria Hjertberg for data entry. We acknowledge Klaus Bjerregaard and Ann-Sofi Hörstedt for providing statistics on breast cancer patients operated in the Skåne University Hospital in Lund. This work was supported by grants from The Swedish Cancer Society (CAN2014/465); the Swedish Research Council (K2012-54X-22027-01-3); the Medical Faculty at Lund University; the Mrs Berta Kamprad Foundation (BKS19/2014, BKS27/2015); the Gunnar Nilsson Foundation; the Swedish Breast Cancer Group (BRO); the South Swedish Health Care Region (Region Skåne ALF 10622); Konung Gustaf V:s Jubileumsfond; and the Lund Hospital Fund. The funding agencies had no role in design of the study; the collection, analysis, and interpretation of the data; the writing of the manuscript; nor the decision to submit the manuscript for publication.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

- Abramowitz MC, Li T, Morrow M, Anderson PR, Bleicher RJ, Goldstein LJ, Swaby R, Nicolau N, Freedman GM (2010) History of smoking is associated with younger age at diagnosis of breast cancer. *Breast J* **16**: 344–349.
- Albanes D, Jones DY, Micozzi MS, Mattson ME (1987) Associations between smoking and body weight in the US population: analysis of NHANES II. *Am J Public Health* **77**: 439–444.
- An Y, Kiang A, Lopez JP, Kuo SZ, Yu MA, Abhold EL, Chen JS, Wang-Rodriguez J, Ongkeko WM (2012) Cigarette smoke promotes drug resistance and expansion of cancer stem cell-like side population. *PLoS One* **7**: e47919.
- Baglietto L, English DR, Hopper JL, MacInnis RJ, Morris HA, Tilley WD, Krishnan K, Giles GG (2009) Circulating steroid hormone concentrations in postmenopausal women in relation to body size and composition. *Breast Cancer Res Treat* **115**: 171–179.
- Barbieri RL, Gochberg J, Ryan KJ (1986) Nicotine, cotinine, and anabasine inhibit aromatase in human trophoblast *in vitro*. *J Clin Invest* **77**: 1727–1733.
- Baron JA (1984) Smoking and estrogen-related disease. *Am J Epidemiol* **119**: 9–22.
- Barrett-Connor E, Khaw KT (1989) Cigarette smoking and increased central adiposity. *Ann Intern Med* **111**: 783–787.
- Berube S, Lemieux J, Moore L, Maunsell E, Brisson J (2014) Smoking at time of diagnosis and breast cancer-specific survival: new findings and systematic review with meta-analysis. *Breast Cancer Res* **16**: R42.
- Bishop JD, Killelea BK, Chaggar AB, Horowitz NR, Lannin DR (2014) Smoking and breast cancer recurrence after breast conservation therapy. *Int J Breast Cancer* **2014**: 327081.
- Björntorp P (1997) Hormonal control of regional fat distribution. *Hum Reprod* **12**(Suppl 1): 21–25.
- Braithwaite D, Izano M, Moore DH, Kwan ML, Tammemagi MC, Hiatt RA, Kerlikowske K, Kroenke CH, Sweeney C, Habel L, Castillo A, Weltzien E, Caan B (2012) Smoking and survival after breast cancer diagnosis: a prospective observational study and systematic review. *Breast Cancer Res Treat* **136**: 521–533.
- Bågeman E, Ingvar C, Rose C, Jernström H (2008) Coffee consumption and CYP1A2*1F genotype modify age at breast cancer diagnosis and estrogen receptor status. *Cancer Epidemiol Biomarkers Prev* **17**: 895–901.
- Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M, Coombes C, Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R (2010) Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. *J Clin Oncol* **28**: 509–518.
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2014) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* **136**: E359–E386.

- Grimm SW, Dyroff MC (1997) Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase. *Drug Metab Dispos* **25**: 598–602.
- Guha P, Bandyopadhyaya G, Polumuri SK, Chumsri S, Gade P, Kalvakolanu DV, Ahmed H (2014) Nicotine promotes apoptosis resistance of breast cancer cells and enrichment of side population cells with cancer stem cell-like properties via a signaling cascade involving galectin-3, alpha9 nicotinic acetylcholine receptor and STAT3. *Breast Cancer Res Treat* **145**: 5–22.
- Hoff CM, Grau C, Overgaard J (2012) Effect of smoking on oxygen delivery and outcome in patients treated with radiotherapy for head and neck squamous cell carcinoma – a prospective study. *Radiother Oncol* **103**: 38–44.
- Holmes MD, Murin S, Chen WY, Kroenke CH, Spiegelman D, Colditz GA (2007) Smoking and survival after breast cancer diagnosis. *Int J Cancer* **120**: 2672–2677.
- Huzell L, Persson M, Simonsson M, Markkula A, Ingvar C, Rose C, Jernström H (2015) History of oral contraceptive use in breast cancer patients: impact on prognosis and endocrine treatment response. *Breast Cancer Res Treat* **149**: 505–515.
- Jernström H, Bågeman E, Rose C, Jönsson PE, Ingvar C (2009) CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients. *Br J Cancer* **101**: 1817–1823.
- Jordan VC (2006) The science of selective estrogen receptor modulators: concept to clinical practice. *Clin Cancer Res* **12**: 5010–5013.
- Kabat GC, Kim M, Phipps AI, Li CI, Messina CR, Wactawski-Wende J, Kuller L, Simon MS, Yasmeen S, Wassertheil-Smoller S, Rohan TE (2011) Smoking and alcohol consumption in relation to risk of triple-negative breast cancer in a cohort of postmenopausal women. *Cancer Causes Control* **22**: 775–783.
- Kadohama N, Shintani K, Osawa Y (1993) Tobacco alkaloid derivatives as inhibitors of breast cancer aromatase. *Cancer Lett* **75**: 175–182.
- Kamdem LK, Flockhart DA, Desta Z (2011) *In vitro* cytochrome P450-mediated metabolism of exemestane. *Drug Metab Dispos* **39**: 98–105.
- Kim S, Taylor JA, Milne GL, Sandler DP (2013) Association between urinary prostaglandin E2 metabolite and breast cancer risk: a prospective, case-cohort study of postmenopausal women. *Cancer Prev Res (Phila)* **6**: 511–518.
- Kwok S, Canoy D, Soran H, Ashton DW, Lowe GD, Wood D, Humphries SE, Durrington PN (2012) Body fat distribution in relation to smoking and exogenous hormones in British women. *Clin Endocrinol (Oxf)* **77**: 828–833.
- London SJ, Colditz GA, Stampfer MJ, Willett WC, Rosner BA, Speizer FE (1989) Prospective study of smoking and the risk of breast cancer. *J Natl Cancer Inst* **81**: 1625–1631.
- Lundin KB, Henningson M, Hietala M, Ingvar C, Rose C, Jernström H (2011) Androgen receptor genotypes predict response to endocrine treatment in breast cancer patients. *Br J Cancer* **105**: 1676–1683.
- Manjer J, Andersson I, Berglund G, Bondesson L, Garne JP, Janzon L, Malina J, Matson S (2000) Survival of women with breast cancer in relation to smoking. *Eur J Surg* **166**: 852–858.
- Manjer J, Malina J, Berglund G, Bondesson L, Garne JP, Janzon L (2001) Smoking associated with hormone receptor negative breast cancer. *Int J Cancer* **91**: 580–584.
- Markkula A, Bromée A, Henningson M, Hietala M, Ringberg A, Ingvar C, Rose C, Jernström H (2012a) Given breast cancer, does breast size matter? Data from a prospective breast cancer cohort. *Cancer Causes Control* **23**: 1307–1316.
- Markkula A, Hietala M, Henningson M, Ingvar C, Rose C, Jernström H (2012b) Clinical profiles predict early nonadherence to adjuvant endocrine treatment in a prospective breast cancer cohort. *Cancer Prev Res (Phila)* **5**: 735–745.
- Markkula A, Simonsson M, Rosendahl AH, Gaber A, Ingvar C, Rose C, Jernström H (2014) Impact of COX2 genotype, ER status and body constitution on risk of early events in different treatment groups of breast cancer patients. *Int J Cancer* **135**: 1898–1910.
- Molarius A, Seidell JC, Kuulasmaa K, Dobson AJ, Sans S (1997) Smoking and relative body weight: an international perspective from the WHO MONICA Project. *J Epidemiol Community Health* **51**: 252–260.
- Morris KT, Toth-Fejel S, Schmidt J, Fletcher WS, Pommier RF (2001) High dehydroepiandrosterone-sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: a renewed role for adrenalectomy. *Surgery* **130**: 947–953.
- Nechuta S, Chen WY, Cai H, Poole EM, Kwan ML, Flatt SW, Patterson RE, Pierce JP, Caan BJ, Ou Shu X (2016) A pooled analysis of post-diagnosis lifestyle factors in association with late estrogen-receptor-positive breast cancer prognosis. *Int J Cancer* **138**: 2088–2097.
- Park JY, Pillinger MH, Abramson SB (2006) Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. *Clin Immunol* **119**: 229–240.
- Passarelli MN, Newcomb PA, Hampton JM, Trentham-Dietz A, Titus LJ, Egan KM, Baron JA, Willett WC (2016) Cigarette smoking before and after breast cancer diagnosis: mortality from breast cancer and smoking-related diseases. *J Clin Oncol* **34**: 1315–1322.
- Pierce JP, Patterson RE, Senger CM, Flatt SW, Caan BJ, Natarajan L, Nechuta SJ, Poole EM, Shu XO, Chen WY (2014) Lifetime cigarette smoking and breast cancer prognosis in the after Breast Cancer Pooling Project. *J Natl Cancer Inst* **106**: djt359.
- Public Health Agency of Sweden (Folkhälsomyndigheten) (2013) Tobaksvanor tidsserier och regionala resultat 2013. Available at <http://www.folkhalsomyndigheten.se/amnesomraden/statistik-och-undersokningar/enkater-och-undersokningar/nationella-folkhalsoenkaten/levnadsvanor/tobaksvanor/>.
- Rastelli F, Crispino S (2008) Factors predictive of response to hormone therapy in breast cancer. *Tumori* **94**: 370–383.
- Ringberg A, Bågeman E, Rose C, Ingvar C, Jernström H (2006) Of cup and bra size: reply to a prospective study of breast size and premenopausal breast cancer incidence. *Int J Cancer* **119**: 2242–2243; author reply 2244.
- Schrenk D, Brockmeier D, Morike K, Bock KW, Eichelbaum M (1998) A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers. *Eur J Clin Pharmacol* **53**: 361–367.
- Seibold P, Vrieling A, Heinz J, Obi N, Sinn HP, Flesch-Janys D, Chang-Claude J (2014) Pre-diagnostic smoking behaviour and poorer prognosis in a German breast cancer patient cohort – differential effects by tumour subtype, NAT2 status, BMI and alcohol intake. *Cancer Epidemiol* **38**: 419–426.
- Simonsson M, Markkula A, Bendahl PO, Rose C, Ingvar C, Jernström H (2014) Pre- and postoperative alcohol consumption in breast cancer patients: impact on early events. *Springerplus* **3**: 261.
- Simonsson M, Veerla S, Markkula A, Rose C, Ingvar C, Jernström H (2016) CYP1A2 – a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients. *BMC Cancer* **16**: 256.
- Subbaramaiah K, Morris PG, Zhou XK, Morrow M, Du B, Giri D, Kopelovich L, Hudis CA, Dannenberg AJ (2012) Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. *Cancer Discov* **2**: 356–365.
- Trevino JG, Pillai S, Kunigal S, Singh S, Fulp WJ, Centeno BA, Chellappan SP (2012) Nicotine induces inhibitor of differentiation-1 in a Src-dependent pathway promoting metastasis and chemoresistance in pancreatic adenocarcinoma. *Neoplasia* **14**: 1102–1114.
- Tsuchiya Y, Nakajima M, Yokoi T (2005) Cytochrome P450-mediated metabolism of estrogens and its regulation in human. *Cancer Lett* **227**: 115–124.
- United States Department of Health and Human Services (2010) *How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General* United States Department of Health and Human Services Atlanta, GA, USA.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.